Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06976268
PHASE2/PHASE3

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Sponsor: Biohaven Therapeutics Ltd.

View on ClinicalTrials.gov

Summary

A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

Official title: A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

Key Details

Gender

All

Age Range

40 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

550

Start Date

2025-05-28

Completion Date

2027-09

Last Updated

2026-01-14

Healthy Volunteers

No

Interventions

DRUG

BHV-8000

BHV-8000 10 mg. Participants will take blinded investigational product (IP) once daily

DRUG

BHV-8000

BHV-8000 20 mg. Participants will take blinded investigational product (IP) once daily

DRUG

Placebo

Matching placebo taken once daily

Locations (15)

Site-049

Birmingham, Alabama, United States

Site-041

Los Angeles, California, United States

Site-031

Farmington, Connecticut, United States

Site-028

New Haven, Connecticut, United States

Site-038

Atlantis, Florida, United States

Site-017

Boca Raton, Florida, United States

Site-051

Maitland, Florida, United States

Site-027

Chicago, Illinois, United States

Site-071

Boston, Massachusetts, United States

Site-015

Farmington Hills, Michigan, United States

Site-044

Chesterfield, Missouri, United States

Site-005

New York, New York, United States

Site-091

Portland, Oregon, United States

Site-043

Round Rock, Texas, United States

Site-007

Bellevue, Washington, United States